Supernus PharmaceuticalsSUPN
SUPN
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
323% more call options, than puts
Call options by funds: $994K | Put options by funds: $235K
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
15% more capital invested
Capital invested by funds: $1.87B [Q3] → $2.15B (+$285M) [Q4]
7% more funds holding
Funds holding: 270 [Q3] → 290 (+20) [Q4]
6% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 95
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1.1% less ownership
Funds ownership: 108.8% [Q3] → 107.71% (-1.1%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$36
14%
upside
Avg. target
$36
14%
upside
High target
$36
14%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Cantor Fitzgerald Kristen Kluska 30% 1-year accuracy 32 / 108 met price target | 14%upside $36 | Neutral Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 21 articles about SUPN published over the past 30 days
Neutral
Accesswire
9 hours ago
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Supernus Pharmaceuticals, Inc. Investment
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 day ago
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses.
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
4 days ago
SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc.
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
5 days ago
ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
6 days ago
Supernus Pharmaceuticals, Inc. (SUPN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN)
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Charts implemented using Lightweight Charts™